Development of MDCO-216, an investigational cholesterol efflux promoter, discontinued due to poor efficacy
Immediate discontinuation of the clinical development program for MDCO-216, an investigational cholesterol efflux promoter, was announced.
Data from the MILANO-PILOT trial did not show drug effects ...
read article